



RNS Number : 9135P

Integrated Diagnostics Holdings PLC

24 May 2024

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELATIVE LAWS OF SUCH JURISDICTION.**

**THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.**

### **Publication of Circular and Notice of Extraordinary General Meeting**

**24 May 2024**

On 16 May 2024, Integrated Diagnostics Holdings plc ("**IDH**" or the "**Company**") announced that it was proposing to delist its shares from the Egyptian Exchange ("**EGX**"), whilst maintaining its existing standard listing on the London Stock Exchange.

Further to that announcement, the Company announces that it now intends to proceed with the proposed delisting of its shares from the EGX and has today published a circular containing further details of the proposed delisting and the necessary shareholder resolutions to be considered and, if thought fit, approved at an Extraordinary General Meeting ("**EGM**") to be convened and the Notice of EGM (the "**Circular**").

The EGM will be held on Wednesday, 12 June 2024 at 1.00 pm (British Summer Time ("**BST**")) / 3.00 pm local time (Eastern European Summer Time ("**EEST**")) at the Headquarters of Integrated Diagnostics Holdings plc, Building F7, Smart Village, Giza, Egypt.

If you are unable to attend the EGM but would like to vote on the resolutions, kindly request to submit your proxy votes online at <https://www.signalshares.com/> or via CREST in accordance with the instructions set out in note 2 of the Explanatory Notes to the Notice of EGM. Shareholders are strongly encouraged to submit their proxy votes online at <https://www.signalshares.com/> or via CREST where applicable. Proxy votes must be received by 1.00 pm (BST) / 3.00 pm local time (EEST) on Monday, 10 June 2024.

The Board of Directors of the Company (the "**Board**") remains keen to encourage engagement with shareholders. To this end, the Board would like to invite questions from shareholders in advance of and during the EGM. Should shareholders wish to submit questions to the Board prior to the deadline for proxy voting they can do so, and these will be responded to on an individual basis. In addition, the Board will offer shareholders the opportunity to dial into the EGM, at which time they can also submit questions to the Board.

Shareholders wishing to access the dial-in facility or submit questions are asked to email Tarek Yehia at [tarek.yehia@idh.com](mailto:tarek.yehia@idh.com) by close of business on Wednesday, 5 June 2024.

A copy of the Circular will shortly be available on the Company's website: <https://www.idhcorp.com/> and for inspection on the National Storage Mechanism: <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

For further information please contact:

**Integrated Diagnostics Holdings plc**

**Tarek Yehia**

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | [tarek.yehia@idhcorp.com](mailto:tarek.yehia@idhcorp.com)

**Company Secretary**

**Company Matters**

[IDHLondon@linkgroup.co.uk](mailto:IDHLondon@linkgroup.co.uk)

-Ends-

**Important disclaimers (including in relation to securities law restrictions)**

This announcement is for information purposes only and is not intended to and does not constitute or form part of an investment recommendation or any offer to buy or sell or subscribe for or any invitation to buy, sell or subscribe for securities in any jurisdiction. Any decision or response in relation to the proposed delisting of the Company's shares from the EGX should be made solely on the basis of the information contained in the Circular.

This announcement may contain certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "anticipates", "estimates", "aims", "anticipates", "assumes", "believes", "could", "estimates", "expects", "forecasts", "intends", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would" or, in each case, their negatives or other similar expressions, which are intended to identify a statement as forward-looking. This applies in particular, to statements containing information on future financial results, plans, or expectations regarding business operations, management, future growth or profitability and general economic and regulatory conditions and other matters affecting the Company and its subsidiaries (the "**Group**").

Forward-looking statements reflect the current views of the Group's management ("**Management**") on future performance which are based on the assumptions of the Management and involve known and unknown risks, uncertainties and other factors that may cause the Group's actual results, performance or achievements to be materially different from those currently expected, results, performance or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause the Group's actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements.

The Group's business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate or prediction to differ materially from those expressed or implied by the forward-looking statements contained in this announcement. The information, opinions and forward-looking statements contained in this announcement are only as at its date and are subject to change without notice. Save as required by applicable law, the Group does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUSAVRSSUVUAR